These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 30063969

  • 1. Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions.
    Ernst J, Klinger-Strobel M, Arnold K, Thamm J, Hartung A, Pletz MW, Makarewicz O, Fischer D.
    Eur J Pharm Biopharm; 2018 Oct; 131():120-129. PubMed ID: 30063969
    [Abstract] [Full Text] [Related]

  • 2. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
    Bahamondez-Canas TF, Zhang H, Tewes F, Leal J, Smyth HDC.
    Mol Pharm; 2018 Apr 02; 15(4):1643-1652. PubMed ID: 29514003
    [Abstract] [Full Text] [Related]

  • 3. Nanometric ion pair complexes of tobramycin forming microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
    Sardo C, Di Domenico EG, Porsio B, De Rocco D, Santucci R, Ascenzioni F, Giammona G, Cavallaro G.
    Int J Pharm; 2019 May 30; 563():347-357. PubMed ID: 30935918
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms.
    Kennedy S, Beaudoin T, Yau YC, Caraher E, Zlosnik JE, Speert DP, LiPuma JJ, Tullis E, Waters V.
    Antimicrob Agents Chemother; 2016 Jan 30; 60(1):348-55. PubMed ID: 26503664
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J, Abdelghany SM, Quinn DJ, Schmid D, Megaw J, Donnelly RF, Jones DS, Kissenpfennig A, Elborn JS, Gilmore BF, Taggart CC, Scott CJ.
    J Control Release; 2015 Jan 28; 198():55-61. PubMed ID: 25481442
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Improved Biofilm Antimicrobial Activity of Polyethylene Glycol Conjugated Tobramycin Compared to Tobramycin in Pseudomonas aeruginosa Biofilms.
    Du J, Bandara HM, Du P, Huang H, Hoang K, Nguyen D, Mogarala SV, Smyth HD.
    Mol Pharm; 2015 May 04; 12(5):1544-53. PubMed ID: 25793309
    [Abstract] [Full Text] [Related]

  • 9. Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms.
    Armijo LM, Wawrzyniec SJ, Kopciuch M, Brandt YI, Rivera AC, Withers NJ, Cook NC, Huber DL, Monson TC, Smyth HDC, Osiński M.
    J Nanobiotechnology; 2020 Feb 18; 18(1):35. PubMed ID: 32070354
    [Abstract] [Full Text] [Related]

  • 10. Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex.
    Fraser-Pitt D, Mercer D, Lovie E, Robertson J, O'Neil D.
    Antimicrob Agents Chemother; 2016 Oct 18; 60(10):6200-6. PubMed ID: 27503654
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ultrasmall TPGS-PLGA Hybrid Nanoparticles for Site-Specific Delivery of Antibiotics into Pseudomonas aeruginosa Biofilms in Lungs.
    Wan F, Bohr SS, Kłodzińska SN, Jumaa H, Huang Z, Nylander T, Thygesen MB, Sørensen KK, Jensen KJ, Sternberg C, Hatzakis N, Mørck Nielsen H.
    ACS Appl Mater Interfaces; 2020 Jan 08; 12(1):380-389. PubMed ID: 31804792
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Human airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin.
    Müller L, Murgia X, Siebenbürger L, Börger C, Schwarzkopf K, Sewald K, Häussler S, Braun A, Lehr CM, Hittinger M, Wronski S.
    J Antimicrob Chemother; 2018 Oct 01; 73(10):2762-2769. PubMed ID: 29982453
    [Abstract] [Full Text] [Related]

  • 15. Probing the size limit for nanomedicine penetration into Burkholderia multivorans and Pseudomonas aeruginosa biofilms.
    Forier K, Messiaen AS, Raemdonck K, Nelis H, De Smedt S, Demeester J, Coenye T, Braeckmans K.
    J Control Release; 2014 Dec 10; 195():21-8. PubMed ID: 25125326
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In Vitro Activity of a Novel Glycopolymer against Biofilms of Burkholderia cepacia Complex Cystic Fibrosis Clinical Isolates.
    Narayanaswamy VP, Duncan AP, LiPuma JJ, Wiesmann WP, Baker SM, Townsend SM.
    Antimicrob Agents Chemother; 2019 Jun 10; 63(6):. PubMed ID: 30910901
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.